3 Unstoppable Stocks to Buy in 2026 and Hold Forever

Eli Lilly is presented as a high‑growth healthcare compounder driven by GLP‑1 products Mounjaro and Zepbound, a late‑stage weight‑loss candidate retatrutide, work on a GLP‑1 pill and an Nvidia partnership to build an AI/supercomputer‑enabled drug discovery factory; the stock trades at over 50x trailing earnings. American Express reported $53.2 billion in revenue through the first nine months of 2025 (up 9% YoY) and $8.4 billion in net income (up 5%), supported by an affluent customer base and resilient consumer spending, with the stock up more than 20% over the past year. Alphabet generated $124.3 billion in trailing‑four‑quarter earnings with a 32% profit margin and a roughly $4 trillion market cap, reinforcing its capacity to fund acquisitions and long‑term growth across Google, YouTube, Waymo and Gemini.

Analysis

Market structure: Winners are LLY (GLP‑1 and pipeline upside), GOOG/GOOGL (ad/margin optionality, AI war chest) and AXP (affluent consumer resilience). Losers include smaller GLP‑1 rivals and commoditized card issuers as Amex captures higher‑end spend; pricing power for LLY and Alphabet allows above‑industry margins (LLY >50x P/E signals elevated expectations). Supply/demand: GLP‑1 demand remains strong; manufacturing/CMO constraints and specialized fill/finish capacity are the next bottlenecks, favoring firms that secure capacity (Lilly + NVDA AI factory is strategic long lead time investment).

Risk assessment: Tail risks include regulatory pricing/marketing interventions on GLP‑1s, a negative retatrutide safety/efficacy readout, credit deterioration hitting AXP, or antitrust/ privacy action versus Alphabet. Time horizons: immediate (days) — earnings/quarterly prints and macro jobs numbers; short (1–6 months) — trial readouts, regulatory commentary; long (1–5 years) — AI factory ROI and durable market share shifts. Hidden dependencies: LLY’s revenue concentration in GLP‑1s and third‑party manufacturing; AXP’s exposure to affluent discretionary cycles; Alphabet’s reliance on ad CPMs tied to macro and search intent.

Trade implications: Size tactical longs 1–3% of portfolio: buy LLY 12–18 month LEAPS call spreads to cap cost and target asymmetric upside if retatrutide/Kisunla catalysts hit; add 1–2% core long GOOG on 5–10% pullbacks and sell 3–6 month covered calls to monetize; overweight AXP (1–2%) into next 2 quarters given resilient spend but hedge with a 6–9 month put if consumer credit indicators (delinquency rate +50bp) deteriorate. Use long GOOG / short XHB or ad‑sensitive media as a pair trade if ad weakness appears.

Contrarian angles: Consensus understates downside to multiples — LLY’s >50x trailing EPS requires flawless drug launches; a single major safety/regulatory shock could compress multiples >20–30% rapidly. The NVDA‑Lilly AI factory story is early — expect 2–5 years to materialize; markets may overpay for promise today. Action: monitor quarterly GLP‑1 revenue share and FDA trial calendars; if GLP‑1 revenue growth slows by >10 percentage points sequentially, reduce LLY exposure by half.

Key Decisions for Investors

• Establish a 1–2% portfolio long in LLY via 12–18 month LEAPS call spread (buy calls, sell higher strike calls) to capture retatrutide/Kisunla upside while capping premium; reduce position by 50% if sequential GLP‑1 revenue growth decelerates >10ppt or if major safety flags emerge.
• Add a 1–3% core long in GOOG/GOOGL on any 5–10% pullback; monetize near‑term theta by selling 3–6 month covered calls (strike ~5–10% OTM) and consider buying 9–12 month protective puts if ad CPMs drop >10% QoQ.
• Overweight AXP by 1–2% into the next 2 quarters to ride affluent consumer resilience; hedge tail risk with 6–9 month puts sized at 25–50% of the long notional if consumer delinquency rates rise >50bp or unemployment surprises by +0.5pp.
• Implement a pair trade: long LLY (1%) / short a broader healthcare ETF or mid‑cap GLP‑1 competitor (1%) to isolate product/capital allocation execution risk — re‑balance after each quarterly print or FDA milestone.
• Do not pay up for NVDA‑Lilly AI narrative in public markets; treat the NVDA partnership as a 2–5 year optionality — only increment exposure if concrete factory milestones (site selection, permitting, first compute install) are publicly confirmed.